638 related articles for article (PubMed ID: 29093096)
21. A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses.
Rodriguez L; Nogales A; Murcia PR; Parrish CR; Martínez-Sobrido L
Vaccine; 2017 Aug; 35(34):4374-4381. PubMed ID: 28709557
[TBL] [Abstract][Full Text] [Related]
22. A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.
Baz M; Paskel M; Matsuoka Y; Zengel J; Cheng X; Treanor JJ; Jin H; Subbarao K
J Virol; 2015 Feb; 89(3):1652-9. PubMed ID: 25410860
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA hsa-miR-324-5p Suppresses H5N1 Virus Replication by Targeting the Viral PB1 and Host CUEDC2.
Kumar A; Kumar A; Ingle H; Kumar S; Mishra R; Verma MK; Biswas D; Kumar NS; Mishra A; Raut AA; Takaoka A; Kumar H
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045983
[TBL] [Abstract][Full Text] [Related]
24. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
[TBL] [Abstract][Full Text] [Related]
25. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.
Uraki R; Kiso M; Iwatsuki-Horimoto K; Fukuyama S; Takashita E; Ozawa M; Kawaoka Y
J Virol; 2013 Jul; 87(14):7874-81. PubMed ID: 23658445
[TBL] [Abstract][Full Text] [Related]
26. Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.
Shcherbik S; Pearce N; Balish A; Jones J; Thor S; Davis CT; Pearce M; Tumpey T; Cureton D; Chen LM; Villanueva J; Bousse TL
PLoS One; 2015; 10(9):e0138951. PubMed ID: 26405798
[TBL] [Abstract][Full Text] [Related]
27. Live attenuated influenza A virus vaccine protects against A(H1N1)pdm09 heterologous challenge without vaccine associated enhanced respiratory disease.
Gauger PC; Loving CL; Khurana S; Lorusso A; Perez DR; Kehrli ME; Roth JA; Golding H; Vincent AL
Virology; 2014 Dec; 471-473():93-104. PubMed ID: 25461535
[TBL] [Abstract][Full Text] [Related]
28. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
29. A Promising IFN-Deficient System to Manufacture IFN-Sensitive Influenza Vaccine Virus.
Chen C; Fan W; Li J; Zheng W; Zhang S; Yang L; Liu D; Liu W; Sun L
Front Cell Infect Microbiol; 2018; 8():127. PubMed ID: 29765910
[TBL] [Abstract][Full Text] [Related]
30. Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets.
Jang YH; Byun YH; Lee DH; Lee KH; Lee YJ; Lee YH; Park JK; Song CS; Seong BL
Vaccine; 2013 Feb; 31(9):1320-7. PubMed ID: 23313655
[TBL] [Abstract][Full Text] [Related]
31. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity.
Seo KY; Han SJ; Cha HR; Seo SU; Song JH; Chung SH; Kweon MN
J Immunol; 2010 Sep; 185(6):3610-9. PubMed ID: 20709955
[TBL] [Abstract][Full Text] [Related]
32. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
33. A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
Baz M; Paskel M; Matsuoka Y; Zengel JR; Cheng X; Treanor JJ; Jin H; Subbarao K
J Virol; 2015 Jul; 89(13):6907-17. PubMed ID: 25903333
[TBL] [Abstract][Full Text] [Related]
34. Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method.
Long Y; Ma L; Liu Z; Song S; Geng X; Yang F; Guo Q; Li Z; Li W; Liao G
Hum Vaccin Immunother; 2018 Mar; 14(3):615-622. PubMed ID: 29064728
[TBL] [Abstract][Full Text] [Related]
35. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
36. Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.
Hughes HR; Vincent AL; Brockmeier SL; Gauger PC; Pena L; Santos J; Braucher DR; Perez DR; Loving CL
Clin Vaccine Immunol; 2015 Oct; 22(10):1109-20. PubMed ID: 26291090
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
[TBL] [Abstract][Full Text] [Related]
38. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
39. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
[TBL] [Abstract][Full Text] [Related]
40. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1.
Rathnasinghe R; Salvatore M; Zheng H; Jangra S; Kehrer T; Mena I; Schotsaert M; Muster T; Palese P; García-Sastre A
Sci Rep; 2021 Nov; 11(1):22164. PubMed ID: 34773048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
